Diagnostic moléculaire des hémopathies lymphoïdes matures Molecular diagnosis of mature lymphoproliferative disorders

The understanding of the molecular mechanisms associated to lymphoid neoplasia has significantly improved in recent years due to technological advances. Molecular markers have been identified, allowing initial diagnosis. Genomic rearrangements can help to affirm clonality or indicate the disease entity. Some markers are also researched for their prognostic value. Finally, some rearrangements can be used for residual disease assessment during clinical course. To cite this journal: Oncologie 13 (2011).

[1]  Elias Campo,et al.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.

[2]  W. Klapper,et al.  Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. , 2010, Blood.

[3]  L. Staudt,et al.  SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype , 2009, Haematologica.

[4]  H. Pospíšilová,et al.  Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. , 2008, Blood.

[5]  T. Molina,et al.  Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936 , 2007, Leukemia.

[6]  L. Staudt,et al.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. , 2005, Blood.

[7]  R. Foà,et al.  Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. , 2005, Blood.

[8]  D. de Jong,et al.  Lack of Bcl‐2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation , 2005, The Journal of pathology.

[9]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[10]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[11]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[12]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[13]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.